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Summary 
The hypothesis that the type II receptor (RII) acts as a decoy for interleukin-1  (IL-1) was tested 
by gene transfer in cells expressing only the type I receptor (8387 fibroblasts). RII-transfected 
cells showed defective responsiveness to IL-1 in terms of NFkB activation, cytokine gene ex- 
pression and production.  Blocking monoclonal antibodies against RII restored the capacity of 
RII-transfected cells  to respond to IL-113. Hence defective IL-1 responsiveness of RlI-trans- 
fected cells  requires surface expression of the molecule. RII-transfected cells showed normal 
responsiveness to TNF, which shares functional properties and elements in the signal transduc- 
tion pathway with IL-1. Cells transfected with a deletion mutant of RII missing 26 of 29 amino 
acids  of the cytoplasmic portion of the molecule showed impaired responsiveness to IL-1. Cells 
transfected with  the  full-length  or the  cytoplasmic deletion  mutant  of RII released copious 
amounts of RII in the supernatant. However, transfected cells showed defective responsiveness 
to brief exposure to IL-1, in the absence of measurable released RII. These results indicate that 
impairment of the responsiveness to IL-1 following RII gene transfer was dependent upon sur- 
face expression of the molecule, specific for IL-1 and unaffected by truncation of the cytoplas- 
mic  portion.  Thus,  the  type  II  "receptor"  is  a  decoy  surface  molecule,  regulated  by anti- 
inflammatory signals,  whose only known function is to capture and block IL-1. 
I 
nterleukin-1  (IL-1) is the term for two polypeptide me- 
.diators  (IL-loL and  IL-113),  which  are  among the  most 
potent and multifunctional cell activators described in im- 
munology and cell biology. The spectrum of action oflL-1 
encompasses cells  of hematopoietic origin, from immature 
precursors  to  differentiated  leukocytes,  vessel  wall  ele- 
ments, cells of mesenchymal, nervous and epithelial origin 
(1, 2). Occupancy of few, perhaps one, receptors per cell is 
sufficient to ehcit cellular responses. 
The production and action oflL-1 are regulated by mul- 
tiple control pathways, some of which  unique  to this cy- 
tokine. This complexity and uniqueness is best represented 
by the term "IL-1 system" (3). The IL-1 system consists of 
1Abbreviations used in this paper: DSS, disuccinimidyl suberate; ICE, IL-1- 
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the  2  agonists,  IL-lot and IL-113, a specific activation sys- 
tem (IL-1--converting enzyme lICE]), a receptor antagonist 
(IL-lra)  produced  in  different  isoforms  (4,  5),  and  two 
high-affinity surface binding molecules (reviewed in refer- 
ence 3). 
Two receptors for IL-1, termed type I  and  II (RI and 
RII) have been identified  and  cloned  (6-8).  RI  and  RII 
bind IL-1 independently of each other (9) and their relative 
amount varies considerably in cells of different lineages (for 
review see reference 3). In a number of different cell types, 
IL-1 activity appears to be mediated exclusively by RI (10-- 
13).  As  illustrated  by endothelial  cells,  RII is  dispensable 
and  RI  is  sufficient  to  respond  to  low  concentrations  of 
IL-1  with  an extremely diversified set of functional alter- 
ations  (14,  15).  Even in myelomonocytic cells,  which  ex- 
press predominantly RII, studies with blocking antibodies 
suggest that IL-1 acts exclusively via minute amounts of RI 
(10,  13).  Antibody blocking experiments suggest that RII 
acts as a decoy target for IL-1, sequestering the agonist and 
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Consistently with this model of function of RII, molecules 
with  anti-inflammatory activity,  including glucocorticoid 
hormones, IL-4 and IL-13, induce augmented expression 
and release of RII (13,  16,  17)  and a RII-related molecule 
expressed by poxviruses is important for pathogenicity (18, 
19).  Chemoattractants cause rapid shedding ofRII, a phe- 
nomenon interpreted  as  a  means  to  buffer  IL-1  leaking 
from sites ofintlammation (20). 
The  concept  of a  high affinity  binding,  nonsignaling 
molecule,  whose  only function is  to  prevent  the  ligand 
from interacting with the true receptor on the same cell, is 
without precedent. In an effort to test the "decoy" model 
of function of RJI directly, we performed gene transfer ex- 
periments. Evidence is presented that  transfection of RII 
causes inhibition of responsiveness to  IL-1, which is  spe- 
cific for IL-1, mediated by surface expressed RII, and inde- 
pendent of the cytoplasmic portion of the molecule. These 
results are consistent with the hypothesis that RII acts as a 
negative regulator of the IL-1 system. 
Materials  and Methods 
Cells and Transfection.  The human 8387 sarcoma line (21) was 
grown in R.PMI  1640 (Gibco, Glasgow, Scotland) with 10% heat 
inactivated fetal  calf serum  (FCS;  Hyclone, Logan,  UT).  60% 
confluent  cells  were  transfected  by  the  calcium  precipitated 
method with 10 p,g of the plasmid.  After 48 h  transfected  cells 
were  selected  for  hygromicin (Boehringer Mannheim, Mann- 
heim, Germany) resistance  (40 p~g/ml) and the pool of resistant 
cells was further analyzed. 
Constructs.  The full-length cDNA for human IL-1 RII, SalI- 
SalI insert, (7) and a cytoplasmic deletion construct, SalI-BgllI in- 
sert,  (see below)  were  ligated  back  into the  polylinker of the 
pCEP4beta  expression  vector  (Invitrogen,  San  Diego,  CA). 
pCEP4beta is an episomial high copy number expression  vector 
containing the hygromicin resistance gene and the insert cDNA 
under the control of the CMV promoter. A cytoplasmic deletion 
construct in which the  coding region terminates after  the  first 
three  amino acids of the  cytoplasmic  portion (HisArgArg)  was 
constructed, resulting in the insertion of a stop  codon after the 
first three amino acids (aa) of the cytoplasmic portion. 
Northern Analysis.  Total R.NA was isolated by the guanidium 
isothiocyanate  method.  10  p~g  of total  R.NA  was  analyzed  by 
electrophoresis  through 1% agarose/formaldehyde  gels, followed 
by Northern blot transfer to Gene Screen  Plus sheet  (New En- 
gland  Nuclear,  Boston,  MA).  Probes  were:  a  EcoRI-HindllI 
477-bp  fragment from  hlL-1RI  cDNA,  a  EcoRI-SalI 750-bp 
fragment from hlL-1RII cDNA, full-length cDNA ofhMCP-1, 
a BanlI-BanlI 620-bp fragment from hlL-6 cDNA, a full-length 
hlL-8  cDNA,  a  full-length hc-jun  cDNA.  Membranes  were 
washed twice with 2￿  SSC/1% SDS at 60~  and exposed for 18 h 
at -80~  tkNA transfer to membranes was checked by UV irra- 
diation. 
Electrophoresis Mobility Shift Assay.  Nuclear extracts were pre- 
pared as described  (22). Double strand oligonucleotide (5' TGA- 
CAGAGGGGACTTTCCGAGAGGA 3')  was  labeled  with 
[ot-32p]dCTP and polynucleotide kinase and eluted from a G25 
column.  For  binding reactions,  10  p~g  nuclear proteins  were 
mixed with an aliquot of the labeled oligonucleotide (5  ￿  104 
CPM) and 1 p,g/ml poly(dldC)  in 10 p~l of a 10 mM Tris,  pH 
7.5, buffer containing  50 mM NaC1 and 6% (vol/vol) glycerol for 
20  min at  room temperature.  Mixtures were  then electropho- 
resed through a 5% acrylamide, 0.5￿  TBE gel; gel was then dried 
and exposed for autoradiography for a few hours. 
IL-1 Binding.  The number and affinity of surface IL-1 recep- 
tors were determined as described  (13). Cells were detached from 
the  plate  with  5  mM EGTA and washed  with binding buffer 
(RPMI 1640-0.2%  BSA, pH 7.4) and 2  ￿  106 or 2  X  l0  s cells 
were incubated with different concentrations of 12sI-IL-l[3 (spec. 
activity 145 p,  Ci/p,g for 8C and 8C7, 95 txCi/p~g for 83C7 and 
83M, 111  p,  Ci/Ixg for 83C; NEN, Bad Homburg, FRG) in the 
presence or absence of a 200-fold molar excess of cold cytokine 
in 50 Ixl binding buffer at 4~  for 4 h in polystyrene round-bot- 
tomed 96-well microplates  (Falcon, Lincoln Park, NJ) on a shak- 
ing platform.  To separate bound from free 125I-IL-113, cells were 
layered on the top of a 200-pJ cushion of 20% sucrose (Merck)- 
1% BSA in 400-p,l  polypropylene tubes (Beckman Instruments, 
Palo Alto, CA) and centrifuged at 10,000 rpm for 30 s. The cellu- 
lar pellets were counted in a "y-counter.  Next, Scatchard analysis 
was performed by the LIGAND program to  determine the kD 
and numbers of receptors for IL-I[~. 
A~nity Cross-linking.  Cross-linking of surface  and  released 
receptors  was performed as described  (13). Briefly, for surface af- 
finity cross-linking,  1  ￿  107  cells were  incubated in binding 
buffer with 1 nM 125I-IL-113 for 4 h at 4~  After addition of 1 
mM disuccinimidyl suberate  (DSS; Pierce,  Rockford, IL) at 4~ 
for 4 h, the cell pellet was lysed in 100 ml lysis buffer (0.5% Tri- 
ton X-100, 25 mM Hepes,  1 mM PMSF). The debris-free super- 
natant was analyzed by 10% SDS-PAGE under reducing condi- 
tions and dried gels were exposed to autoradiography for 3 h. For 
soluble covalent cross-linking, medium was recovered and 100 Ixl 
were added to 1 nM 125I-IL-l~, with or without a 200 M excess 
of cold IL-I~ or 10 Ixg/ml M1  (blocking mAb anti IL-1 RI) or 
M22 (blocking mAb anti IL-1 RII), and incubated at 4~  for 4 h. 
After addition of 1 mM DSS at 4~  for 30 min, samples were an- 
alyzed by gel electrophoresis  as above and dried gels exposed  to 
autoradiography for 18 h. 
Cytokine Assays and Reagents.  3 ￿  104 cells were plated in 96 
flat-bottomed plates  in 200  ILl tkPMI  +  10%  heat-inactivated 
FCS (culture medium). After 1 d medium was changed with cul- 
ture  medium  containing  stimuli  (recombinant  IL-I[~;  from 
Domp~, L'Aquila, Italy, specific activity 107 U/mg; recombinant 
TNFoL; Basf Knoll, Ludwighafen, Germany, specific activity  6.6 
￿  106  U/mg) and incubation was  continued for an additional 
24 h. The supernatants  were then harvested  and kept at -20~ 
In  some  experiments,  recombinant soluble  RII  expressed  in 
CV-1 EBNA-1 cells (9) was added to the wells before IL-I[3. 
IL-6 was  measured using a  specific ELISA  or as  hybridoma 
growth factor activity on the 7TD1 cell line obtained through the 
courtesy  of Dr. J.  Van Snick (Ludwig  Institute, Bruxelles,  Bel- 
gium) as described  (23). Briefly, 2 ￿  103 cells in 200 la,  l (four rep- 
licates per dilution) were cultured for 72 h  with different  dilu- 
tions of the  culture supernatants  to  be  tested  or  with  control 
medium. The number of cells was assessed by the MTT colori- 
metric test as described  (23). HGF activity resulting in half maxi- 
mal stimulation of target  cell growth was arbitrarily  defined as 1 
unit. The reference standard  used in these  experiments was hu- 
man recombinant IL-6. 
MCP-1 was determined using a recently developed sandwich 
ELISA, with a sensitivity limit of 30 pg/ml (24). IL-8 was mea- 
sured using a specific ELISA with mAb and a polyclonal serum 
(gifts from Dr. M. Ceska, Sandoz, Wien, Austria). Cytokine assays 
were conducted with four replicates and results are mean +  SE. 
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type I (M4 or M1) and the type II (M22) receptor have been de- 
scribed previously (9,  13). A  novel specific  ELISA was  used to 
measure  release  of RII from transfected  cells. The assay is based 
on a poyclonal antiserum and mAb (clone no. 8) raised against the 
RII expressed  in 8387 cells. It has a sensitivity  of"-'300 pg/ml 
(Peri, G., unpublished data). 
Results 
Characterization  of Cells  Transfected with  the  IL-t  Decoy 
RII.  The 8387 cell line was selected for these studies be- 
cause it expresses  only RI by Northern  and PCR  analysis 
(Fig.  1  A  and  reference  15).  Following  transfer  of a  full- 
length  RII  cDNA  under  the  control  of the  CMV  pro- 
moter, high levels ofRII m_RNA were detected (Fig.  1 A). 
It is  important  to  note  that  cells  transfected  with  the  RII 
continued  to  express  RI  at levels  comparable  to  those  of 
parental  or  vector  transfected  cells  (Fig.  1  A).  RII  gene 
transfer was associated with a marked increase in the capac- 
ity of 8387 cells to bind IL-113.  For instance, in the experi- 
ment  shown in  Fig.  1 B,  cells  transfected  with  the  empty 
vector had 167 IL-113 binding sites/cell with a kD of 3.4 ￿ 
10 -1~ M, compared to 3.7  ￿  104  binding sites/cell  (kD 7.1 
￿  10 -1~ M)  for transfected  cells.  Following gene  transfer, 
cross-linking of surface  IL-1  binding molecules  revealed a 
major band  of ~87  kD,  which,  after  taking into  account 
the  labeled  ligand,  corresponds  to  the  molecular  mass  of 
RII (68 kD) (Fig.  1 C). 
Responsiveness to IL- 1 after RII Gene Transfer.  Fig. 2 shows 
typical  experiments  in  which  cells  transfected  with  RII 
were exposed to graded concentrations of IL-I~ (from  10 
pg/ml  to  100  ng/ml)  and  the  response  was  measured  in 
terms  of cytokine  (IL-6,  IL-8,  and  MCP-1)  production. 
Parental 8387 cells or cells transfected with the empty vec- 
tor were exquisitely sensitive to IL-113, with a minimal ac- 
tive concentration for IL-6 production of 10 pg/ml and an 
ED50 of 361  +  84 pg/ml (mean  +  SE) in 12 different ex- 
periments.  RII gene  transfer resulted  in  a marked impair- 
ment  of the  capacity  of 8387  cells  to  respond  to  IL-113. 
Inhibition was observed in three series of experiments cor- 
responding  to  three  independent  transfections  performed 
over a period of 2 yr. The inhibition oflL-1 responsiveness 
was related to the numbers of transfected RII receptors. As 
illustrated  in Fig. 2  A, with 37  ￿  103  RlI/cell,  high con- 
centrations oflL-l[3 (100 ng/ml) reversed the defective re- 
sponsiveness of RII-transfected cells.  With 400 ￿  103  sites/ 
cell,  only a  weak response,  not reaching the haft-maximal 
value was observed. Defective responsiveness  of RII-trans- 
fected  8387  cells  was  not  confined  to  IL-6  production, 
since similar results were obtained when IL-8 (nine experi- 
ments)  and  MCP-1  (13  experiments)  release  were  mea- 
sured  (Fig.  2  B).  Defective  cytokine  production  by RII- 
transfected  cells  was evident  after different  culture  periods 
ranging from 18 to 48 h  (data not shown). RI gene transfer 
under  similar  conditions  augments  the  responsiveness  of 
cells to IL-1 (reference 6 and unpublished). 
Effect of  Anti-IL-1  R  mAb.  Previously characterized and 
used  blocking  mAbs  (9,13)  were  used  to  investigate  the 
role  of the  IL-1  receptors  in  control  and  RII-transfected 
cells.  As expected,  the anti-RI mAb M4 inhibited the  ca- 
pacity of 8387 cells to respond to IL-1 (Fig. 3 A). The same 
mAb also inhibited the weak responsiveness to IL-1 of cells 
expressing high levels of RII after gene transfer.  Blocking 
mAb directed  against RII reverted  the  defect  in  IL-1  re- 
sponsiveness  of cells in which  expression  of this  molecule 
was forced by gene transfer  (Fig.  3 A). Anti-RII mAb did 
not affect cytokine production in parental  or vector-trans- 
fected  cells.  Anti-RII mAb also restored  the  defective  ca- 
pacity of transfected  cells  to  respond  to  IL-1  in  terms  of 
rapid induction of cytokine mRNA  (not shown). In an ef- 
fort to further test the possibility that an undefined "right" 
Figure 1.  Characterization  of RII-transfected cells. (A) Northern blot analysis of  the 1L-1 RI (lanes 1 and 2) or RII (lanes 3 and 4) expression in cells 
transfected with the empty vector (8C, lanes 1 and 3) or with RII (8C7, lanes 2 and 4). The ethidium bromide stained membrane is shown in the right 
part of the panel. (/3) Saturation curve and Scatchard analysis of 12Sl-IL-113  binding to cells transfected with empty vector (8C, Fq) or with decoy RII 
(8C7, n). Number and affinity of sites were calculated by LIGAND program. The scale on the ordinate does not allow showing individual points for 
control cells (8C, 0) in the insert. (C) Affinity  cross-linking  of  surface RII by IzsI-IL-113  in RIl-transfected cells (line 8C7). Molecular  mass standards are 
indicated. 
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Figure 2.  Cytokine production after RII gene transfer. Cells were in- 
cubated with recombinant IL-1~3 for 24 h. (A) Production of IL-6. (O) 
parental 8387; ([]) cells transfected with empty vector (8C line); (I) RI1- 
transfected cells (8C7; 3.7 ￿  104 sites/cell; full-length RII);  (A) A372- 
398 RII-transfected cells (83M; 25 ￿  104 sites/cell); (A) RlI-transfected 
cells (83C7; 40 ￿  104 sites/cell full-length RII). Results are representative 
of 12 experiments performed over a period of 24 mo. (B) Production of 
IL-6, IL-8 and MCP-1. Results are percent of control at a concentration 
of 1 ng/ml IL-113. Open bars, vector control  (8C); hatched bars, RII 
transfected cells (8C7). 
number  of RII may present the ligand to the signal trans- 
ducing RI, in analogy with hgand passing by the p75 TNF 
R  (25),  we studied the  effect of graded concentrations  of 
anti-RII mAb on IL-1  responsiveness. A  similar approach 
was  used after over-expression of the p75  TNF R  in p55 
expressing HeLa cells, and showed amplification of the re- 
sponse to TNF in the presence of suboptimal anti-p75 (25), 
As shown in Fig. 3  B, at concentrations ranging from 5 ng 
to 5  I*g/ml, anti-RII mAb only inhibited and never ampli- 
fied responsiveness to  IL-1  in RII-transfected cells versus 
cells expressing only the RI. 
These  results indicate that inhibition of the response to 
IL-1  after RII  gene  transfer is reversed by blocking anti- 
RII mAb. Hence, defective IL-1 responsiveness in transfec- 
tants requires surface expression of RII. 
Defective NFkB Activation and Induction  of Gene Expression 
in RII-transfected Cells.  It was important to ascertain whether 
RII gene transfer affected early events following interaction 
oflL-1 with cells. Activation of AP-1 and NFkB transloca- 
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Figure 3.  Effect  ofanti-IL-1 R mAb IL-1 responsiveness  of RlI-trans- 
fected cells. (A) Cells transfected  with empty vector (8C, open bars) or RII 
(8C7, hatched bars) were stimulated with 100 pg/ml IL-113  in the presence 
of an irrelevant mAb, or anti-KI m-Ab (M4), or anti-RIl mAb (M22) for 
24 h and IL-6 production was measured. (B) Cells transfected  with empty 
vector (8C, open bars) or RII (8C7, hatched bars) were stimulated with 100 
pg/ml IL-1[3  in the presence of graded doses of M22 mAb (from 5 ng/ml 
to 5 p,g/ml) for 24 h and IL-6 production was measured, 
tion to the nucleus  are involved in IL-l-activated cellular 
responses  (12,  26,  27).  Therefore,  we  investigated NFkB 
activation and expression of immediate early genes in RII- 
transfected cells.  As shown  in  Fig.  4,  NFkB  activation as 
well as induction of cytokine mRNA  expression, was dras- 
tically reduced  in  RII-transfected cells  exposed  to  IL-I~ 
for  1/2-4  h.  Similar  results  were  obtained  when  c-jun 
mRNA  induction was  examined  (not  shown).  Thus,  RII 
gene transfer compromises early events that follow interac- 
tion of IL-1 with signaling ILl. 
Specificity of Defective IL-1 Responsiveness.  TNF has a spec- 
trum  of action and a  signal transduction pathway remark- 
ably similar to that oflL-1 (28-31),  It was therefore impor- 
tant to ascertain the responsiveness of ILII-transfected cells 
to TNF. As shown in Fig. 5, RII-transfected cells, with de- 
fective response to IL-1, produced normal amount of IL-6 
(A)  and  IL-8 (B)  when  exposed to TNF.  Thus,  RII gene 
transfer  selectively impairs  the  response  to  IL-1,  but  not 
that to the functionally related cytokine TNF. 
Inhibition  of lL- I Responsiveness by Truncated RII.  The re- 
sults discussed so far indicate that surface expression of the 
RII following gene transfer specifically inhibits the capacity 
1844  Inhibition oflL-1 by Surface Type II Receptor Figure 4.  NFkB  translocation  and gene expression in Rll-transfected ceils. (A) Cytokine gene expression. Cells were exposed to IL-113 for 2-4 h 
and gene expression  was assessed by northern analysis  with total RNA using IL-6, IL-8 or MCP-1 probes. The amount of RNA blotted was checked by 
ethidium bromide staining  of the membranes. (B) NFkB translocation.  EMSA with nuclear extracts from control (83C) and R.lI-transfected  cells (83C7) 
stimulated witl~ IL-113 for 30 inin. 100￿  excess of cold oligonucleotide  was added to control (cold). 
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of cells to respond to IL-1  via ILI. It was important to in- 
vestigate whether the cytoplasmic portion of the RII, con- 
sisting of 29  amino acids  (7),  played any role in blocking 
IL-1  activity.  Cells  were  transfected with  an ILII  cDNA 
construct encoding the  extracellular and  membrane por- 
tions and missing the cytoplasmic tail from aa 372  to 398. 
As shown in Fig. 6  (A), transfer of the A372-398 ILII gene 
resulted in an increased capacity to bind IL-1, with 2.5  ￿ 
10  s sites/cell and a kD of 8.8  X  10 -9 M.  Cells transfected 
in parallel with  a  construct encoding the  ~lll-length P,,II 
had 4  X  10  s sites/cell and a kD of 5  X  10 -9 M. The differ- 
ent surface binding obtained reflected the levels of mRNA 
in the  two  transfectants (not shown). As shown in Fig.  6 
(B),  expression of a  truncated version of ILII, missing the 
last 26  cytoplasmic amino acids,  resulted in a marked im- 
pairment of the  capacity  of the  cells  to  respond  to  IL-1 
evaluated as MCP-1  or IL-6 production. Taking into ac- 
count the  different number of binding sites in A372-398 
versus intact ILII transfectants (2.5  X  105  versus 4  ￿  10  s 
sites/cell), it is apparent that the cytoplasmic truncation did 
Figure 5.  Selectivity  of defective IL-1 responsiveness.  Cells transfected 
with empty vector (8C, open bars) or RII (8C7, hatched bars) were stimu- 
lated with 100 pg/ml IL-I~ or 10 U/m/TNF~x and IL-6 (A) or IL-8 (B) 
were measured. 
1845  Re et al. (A)  83C: 100 sites/cell; Kd=l x  l 0e-9 
83C7: 4xl 0e+5 sites/cell; Kd=5xl 0e-9 
30000  83M: 2.5x10e+5 sites/cell; Kd=8.8xl0e-9 
0 
40000-  .~.  20000 
o  10000~ 
c,  O~  -  ," .....  "', 
30000  0  20000  40000 
bound 
~ 
20000 
' 
O~  ,  []  []  , 
0  1  2 
E 
v 
E 
t-- 
v 
(2. 
0 
160 
120 
80 
40 
0 
0  101  10  2  10  3 
IL-1  (pg/ml) 
4000 
3000 
2000 
1000 
0 
0  101  102  10  3 
total  (nM)  IL-1  (pg/ml) 
Figure 6.  Inhibition oflL~l responsiveness  by A372-398 RII gene transfer. (A) Saturation curve and Scatchard analysis oflL-l[3 binding to cells trans- 
fected with empty vector (83C U]), with RII (83C7 ") or A372-398 RII (83M A). Number and affinity of  sites were calculated by LIGAND program. 
The scale on the ordinate does not allow showing individual points for control cells (8C [~) in the insert. (B) Cells transfected with empty vector (83C 
[-1), with RII (8C7 m) or A372-398 RII (83M &) were stimulated with graded doses oflL~l~ for 24 h and MCP-1 was measured. (C) Cells transfected 
with empty vector (83C h), with RII (8C7 J) or A372-398 RII (83M A) were stimulated with graded doses of IL-I[~  for 24 h and IL~6 was measured. 
not  affect the  capacity  of the  RII to block IL-1  activity. 
Thus, the cytoplasmic domain is not involved in the capac- 
ity of RII to inhibit responsiveness to IL-1. 
Release of RII after Gene Transfer.  RII is  found in  solu- 
ble form in biological fluids and culture supernatants  (32- 
39).  Release  of the  RII by myelomonocytic cells  is  aug- 
mented by glucocorticoids, IL-4 and IL-13 (!3, 16, 17) and 
induced rapidly by chemoattractants  (20).  It was therefore 
important to investigate whether cells transfected and over- 
expressing RII released this molecule and whether released 
RII accounted for the block in responsiveness to IL-1. Us- 
ing a specific ELISA, we determined that transfected 8387 
cells released the RII with,  in a representative  experiment 
out of three performed,  17.6  +- 5.9 ng/rnl/15  X  104 cells/ 
24 h  (Fig. 7 A). The A372-398 RII was also released from 
transfected  cells  in  amounts  comparable  to the  full length 
RII (24 ng/ml in 24 h).  The  released  soluble  decoy RII, 
was detectable after 9 h of incubation and continued to ac- 
cumulate thereafter. 
In an effort to molecularly identify the immuno-reactive 
RII released from transfected cells  and to determine its ca- 
pacity to bind IL-I~, cross-linking experiments were per- 
formed.  As  shown  in  Fig.  7  B,  supernatants  from  trans- 
fected  cells  contained  an  IL-113 binding  molecule  with  a 
molecular  mass  of 60  kD  after  taking  into  account  the 
ligand.  Competition for cross-linking using blocking anti- 
RI and anti-RII mAb confirmed release of RII from trans- 
fected cells.  Based on quantitative  estimates by ELISA and 
on the molecular mass of the released R, we calculated that 
the  number of released receptors/cell in 24 h  was  13.5  ￿ 
105 (mean of two experiments) for cells expressing 4  ￿  105 
sites/cell  and  2.3  ￿  10  s  for  cells  expressing  0.37  X  105 
sites/cell  (one experiment).  We conclude that nonhemato- 
poietic cells transfected with RII release substantial amounts 
of a soluble  60-kD version of the molecule, which retains 
ligand binding  capacity,  and  that  release  does  not require 
the cytoplasmic portion of the molecule. 
A series of experiments was performed in an effort to es- 
tablish  whether  release  of RII  completely  accounted  for 
defective responsiveness to IL-1. First, cells transfected with 
vector alone or with the RII gene were exposed to differ- 
ent concentrations oflL-lj3 for 1 or 24 h. Since accumula- 
tion  of the  released  RII required  several  hours,  if the  re- 
leased molecule played a dominant role in inhibiting IL-1, 
the prediction was that transfected cells should retain a rela- 
tively higher response to brief (1  h) versus long (24 h)  ex- 
posure  to  IL-1.  Long  (24  h)  exposure  of control  cells  to 
IL-1 resulted in higher responses (Fig. 7 C, open squares ver- 
sus open triangles), with a minimal effective concentration of 
>100 pg/ml and  10 pg/ml for incubation with IL-1  for 1 
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RII in defective  responsiveness  of RII-transfected 
cells. (A)  Release of RII.  Supematants  were col- 
lected at different times of incubation  of RII-trans- 
fected cells (83C7). Released RII was measured us- 
ing a specific ELISA.  (/3) Cross-linking  of released 
RII with 12Sl-IL-113.  Affinity cross-linking of IL-113 
to supernatants of cells transfected with empty vec- 
tor (lane  I)  or RII ( from lane  2 to lane  5).  The 
binding was  competed with cold IL-113 (lane 3), 
M22 mAb (anti-RlI, lane 4) or M1 mAb (anti-RI, 
lane 5). Molecular mass standards are indicated.  (C') 
Defective responsiveness is unaffected by the length 
of exposure  to IL-113. Control and RII transfected 
(83C and 83C7) cells were incubated  with different 
concentrations  of IL-113 for 1 h, washed extensively 
and  fiarther  incubated  in  IL-l-free  medium  for 
23 h. Alternatively  cells were exposed to IL-113 for 
24 h:  (A),  Control cells exposed to IL-113 for 1 h; 
(A)  RII-transfected  cells (83C7)  exposed  for 1 h; 
(E]), Control cells exposed for 24 h; (11), RII-trans- 
fected cells (83C7)  exposed for 24 h.  (D) Effect of 
released RII on IL-1 responsiveness. The 24 h su- 
pernatant  of vector  (8C)  or RII  transfected  cells 
(83C7)  was added  to control 8387  cells. IL-113 (1 
ng/ml) was added  to the culture  for 24 h  and  re- 
sponse was measured  as IL-6 production.  The su- 
pernatant  of RII-transfected cells contained  27 ng/ 
ml of released RII. By way of comparison,  recom- 
binant  RII  (100 ng/ml)  was  added  to  8387  cells 
with IL-113 1 ng/ml. The defective  responsiveness 
to  IL-113 (1  ng/ml)  of the  same  cells  used  as  a 
source of the supernatant  is shown in parallel. 
and  24  h,  respectively.  The.  defect  in  the  capacity  to  re- 
spond  to  IL-lf3  of RII-transfected  cells was  similar after  1 
or 24 h  of exposure to the agonist (Fig. 7  C, closed symbols). 
Finally,  24  h  conditioned  medium  from  RII  transfected 
cells or amounts  in  excess of recombinant  RII were added 
to control cells. As shown in Fig. 7  D  the conditioned me- 
dium  containing  27  ng/ml  of soluble  RII  caused  a  29.6% 
inhibition  of the  activity of I  ng/ml  IL-113,  and  recombi- 
nant RII  (100 ng/ml) caused a 52% of inhibition of the ac- 
tivity of 1 ng/ml  IL-113.  Under the same conditions,  trans- 
fected  cells  (the  source  of conditioned  medium)  showed  a 
more dramatic impairment of the response to IL-113, with a 
77.9% reduction at 1 ng/ml relative to control cells. 
These  results  indicate  that  the  defective  capacity  to  re- 
spond to IL-1 of RII-transfected cells cannot be completely 
accounted  for by release  of a  soluble  version of the mole- 
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cule and  that membrane-bound  RII  contributes  to seques- 
tration of IL-1. 
Discussion 
The  study  presented  here  was  designed  to  test  the  "de- 
coy receptor" model of function of IL-1 RII. Based on the 
model (13),  it was predicted that  expression of the RII ob- 
tained  by  gene  transfer  in  cells  expressing  only RI  should 
result  in  a  decreased  responsiveness  to  IL-1.  Consistently 
with this  prediction,  it was found  that transfer ofRII  gene 
in cells expressing only RI  resulted in defective responsive- 
ness to IL-1. The 8387  sarcoma system was analyzed in de- 
tail, but similar results were obtained with cell lines of dif- 
ferent  lineage,  including  the  myelomonocytic  cell  line 
U937  (not  shown).  U937  cells only express  RI  transcripts and  gene  transfer  resulted  in  expression  of RII  numbers 
similar  to  those  present  on  monocytes.  RII-transfected 
U937  showed  defective  induction  of IL-8  mRNA  (not 
shown).  Therefore these results provide strong direct evi- 
dence,  which  complements previous  data  obtained  using 
blocking mAb (10,  13), that RII is not a signaling molecule 
and that it acts as a molecular trap for IL-1. 
RII-transfected  cells  expressed  normal  levels  of  RI. 
Moreover, blocking mAb directed against RII restored the 
capacity oftransfected cells to respond to IL-1. Conversely, 
blocking mAb directed against RI inhibited the capacity of 
control and RII-transfected cells to respond to IL-1. These 
results exclude that the impairment of IL-1 responsiveness 
of RII-transfected cells is caused by sequestration or inhibi- 
tion  of expression of RI  and  demonstrate  that  the  defect 
depends upon surface expression of RII. 
TNF is an inflammatory cytokine whose spectrum of ac- 
tion,  effects, and signal transduction pathways are remark- 
ably similar to those of IL-1 (28-31).  Ceils transfected with 
IL-1  RII  retained  responsiveness  to  TNF.  Moreover, 
blocking mAb directed against RI or RII did not affect re- 
sponsiveness to  TNF.  Thus,  the  impairment  of IL-1  re- 
sponsiveness oftransfected ceils is specific for IL-1 and does 
not  reflect  interference  with  common transduction  path- 
ways. 
TNF interacts with two receptors, p55 and p75 (40,  41). 
The role of p75 in the regulation of TNF activity is com- 
plex (42).  Under certain conditions it has been shown that 
p75 captures TNF and presents it to the signal transducing 
p55 R  (25).  Transfer of the IL-1 RII gene was never asso- 
ciated  with  amplified  responsiveness  to  IL-1,  even  with 
lines  or  clones  expressing  low  levels  of surface  RII  (not 
shown).  Moreover, following, an approach used for TNF 
receptors (25),  we treated RII-transfected cells with graded 
concentrations  of blocking mAb,  in  search  of a  putative 
"right" concentration of RII suitable to present the ligand 
to the few RI and thus to amplify response to IL-1. These 
efforts  failed  and  cell  lines  expressing  low  levels  of RII 
never showed augmented responsiveness to IL-1. Thus, all 
in all, gene transfer and mAb studies gave no indication that 
the RII can capture the ligand and present it to the signal 
transducing RI. 
RII  is  found  in  the  supernatants  of mitogen  activated 
mononuclear cells, B lymphoblastoid cells and myelomono- 
cytic ceils,  keratinocytes (13,  32-34,  36,  39),  as well as in 
human plasma from healthy donors or patients with sepsis 
(35,  37)  or  inflammatory  synovial  fluids  (35,  38).  Anti- 
inflammatory  agents  that  augment  expression  of RII  in 
PMN  and  monocytes  (glucocorticoids,  IL-4,  IL-13),  also 
cause increased release of the molecule (references 13,  16, 
17 and Colotta, F., and A. Mantovani, unpublished). More 
recently, it was found that chemoattractants cause rapid re- 
lease of RII by activating a performed protease (20).  In the 
present study we found that transfected cells release RII in 
the absence of deliberate stimulation. The reieased RII was 
60  kD in size and retained  the  capacity to bind IL-113, as 
assessed  by  cross-linking.  Intriguingly,  the  classic  soluble 
RII described in culture supernatants is 45 kD (13,  16,  17, 
32-35).  The 60-kD RII found in the supernatant of trans- 
fected  8,387  cells  resembles  the  molecule  released  from 
monocytes (Colotta,  F.,  and A.  Mantovani,  unpublished). 
The molecular basis  and mechanisms for heterogeneity of 
soluble RII as well as its  biological significance remain to 
be defined. 
Several lines of evidence suggest that release of RII does 
not account for the defective IL-1  responsiveness of RII- 
transfected  cells.  First,  the  poor  IL-1  responsiveness  in 
terms  of cytokine  production  was  equally  evident  after 
short (1  h) and long (24 h)  exposure to the agonist, i.e., in 
the absence and presence of substantial amounts of released 
RII.  Second,  the  supernatant  of RII-transfected cells  and 
amounts in  excess of recombinant RII did not inhibit the 
response to IL-113 to an extent as profound as that observed 
in  cells  expressing  surface  RII.  Finally,  carefully  washed 
RII-trasfected cells showed a profound defect in IL-113 in- 
duced NFkB activation, protooncogene and cytokine gene 
expression,  rapid  responses  that  occur  in  the  absence  of 
measurable released RII. Thus,  released RII does not  ac- 
count for defective IL-1 responsiveness and surface expres- 
sion of the molecule plays an important role in unrespon- 
siveness ofRIl transfected cells. One may speculate that the 
surface RII may protect myelomonocytic ceils,  which ex- 
press this molecule as predominant IL-1 receptor and pro- 
duce  copious amounts of IL-113, from excessive autocrine 
stimulation. 
The  mechanism(s)  through  which  surface  RII  inhibits 
IL-1  responsiveness are in part a matter of speculation.  In 
addition  to binding  IL-1, RII could internalize  and scav- 
enge the molecule, acting as scavenger receptor. Evidence 
compatible with a scavenger function  of RII was recently 
obtained in PMN (F. Colotta, unpublished observation). In 
addition surface RII may compete for yet undefined con> 
ponents of the signal transducing RI receptor complex. An 
accessory molecule which  cooperates with  RI  in  binding 
IL-113  (but not IL-lra) was recently identified  (43).  Since 
truncation of the cytoplasmatic portion does not influence 
the  inhibitory  capacity,  one  could  speculate  that  cognate 
recognition of the ligand by RII and by an accessory mole- 
cule could at the same time prevent the ligand and the ac- 
cessory component from interacting with the signaling RI. 
The  transfected  ceil  lines  generated  in  the  present  study 
represent  an invaluable  tool to  further investigate the  in- 
hibitory action of RII. 
The IL-lra competes with IL-1 for binding to the recep- 
tor  and  antagonizes  its  action.  Three  isoforms  of IL-lra 
have been described, two of which are intracellular (5, 44- 
47). Molecules with anti-inflammatory activity such as glu- 
cocorticoids, IL-4 and IL-13, induce augmented expression 
of both IL-lra (48,  49) and RII (13,  16,  17).  IL-lra binds 
the  RI  signaling receptor and,  with  much lower affinity, 
the  membrane-associated and released RII  (7,  17,  38,  50, 
51).  Therefore IL-lra and R II represent pathways of nega- 
tive regulation unique to the IL-1 system which minimally 
cross neutralize each other. 
The results presented here directly demonstrate that RII 
is a nonsignaling molecule that captures IL-1 and blocks its 
1848  Inhibition oflL-1 by Surface Type II Receptor action. The inhibitory capacity of transfected RII depends 
on  surface  expression, is specific for IL-1  and is indepen- 
dent of the cytoplasmic domain of the molecule. Thus, sur- 
face RII is a unique pathway of negative regulation of the 
IL-1 system, potentially a  tool and a  target for therapeutic 
intervention. 
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